Edwards Lifesciences Corp
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| Common Stock · Treasury Stock | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Par Value · Shares · Amount · Additional Paid-in Capital · Retained Earnings · Accumulated Other Comprehensive Loss · Total Edwards Lifesciences Corporation Stockholders' Equity · Noncontrolling Interest · Total Stockholders' Equity | |||||||||||||||||||
| BALANCE AT DECEMBER 31, 2022 | 646.3 | $646.3 | 38.0 | $(4,144.0) | $1,969.3 | $7,590.0 | $(254.9) | $5,806.7 | $— | $5,806.7 | |||||||||
| Net income (loss) | 1,402.4 | 1,402.4 | (3.0) | 1,399.4 | |||||||||||||||
| Other comprehensive income, net of tax | 12.1 | 12.1 | 12.1 | ||||||||||||||||
| Common stock issued under equity plans | 4.2 | 4.2 | 165.7 | 169.9 | 169.9 | ||||||||||||||
| Stock-based compensation expense | 139.4 | 139.4 | 139.4 | ||||||||||||||||
| Purchases of treasury stock | 11.4 | (880.5) | (880.5) | (880.5) | |||||||||||||||
| Changes to noncontrolling interest (Note 9) | — | 72.4 | 72.4 | ||||||||||||||||
| BALANCE AT DECEMBER 31, 2023 | 650.5 | 650.5 | 49.4 | (5,024.5) | 2,274.4 | 8,992.4 | (242.8) | 6,650.0 | 69.4 | 6,719.4 | |||||||||
| Net income (loss) | 4,174.6 | 4,174.6 | (4.9) | 4,169.7 | |||||||||||||||
| Other comprehensive loss, net of tax | (1.7) | (1.7) | (1.7) | ||||||||||||||||
| Common stock issued under equity plans | 4.3 | 4.3 | 175.2 | 179.5 | 179.5 | ||||||||||||||
| Stock-based compensation expense | 163.8 | 163.8 | 163.8 | ||||||||||||||||
| Purchases of treasury stock | 16.8 | (1,167.8) | (1,167.8) | (1,167.8) | |||||||||||||||
| BALANCE AT DECEMBER 31, 2024 | 654.8 | 654.8 | 66.2 | (6,192.3) | 2,613.4 | 13,167.0 | (244.5) | 9,998.4 | 64.5 | 10,062.9 | |||||||||
| Net income (loss) | 1,073.5 | 1,073.5 | (4.1) | 1,069.4 | |||||||||||||||
| Other comprehensive income, net of tax | 6.2 | 6.2 | 6.2 | ||||||||||||||||
| Common stock issued under equity plans | 3.9 | 3.9 | 170.2 | 174.1 | 174.1 | ||||||||||||||
| Stock-based compensation expense | 158.1 | 158.1 | 158.1 | ||||||||||||||||
| Purchases of treasury stock | 11.8 | (899.4) | (899.4) | (899.4) | |||||||||||||||
| Changes to noncontrolling interest (Note 9) | (173.3) | (173.3) | (60.4) | (233.7) | |||||||||||||||
| BALANCE AT DECEMBER 31, 2025 | 658.7 | $658.7 | 78.0 | $(7,091.7) | $2,768.4 | $14,240.5 | $(238.3) | $10,337.6 | $— | $10,337.6 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.